Skip to main content
IRLAB Therapeutics logo

IRLAB Therapeutics — Investor Relations & Filings

Ticker · IRLAB ISIN · SE0012675361 LEI · 549300JAT34LHEI0DH60 ST Manufacturing
Open in API
Filings indexed 157 across all filing types
Latest filing 2024-05-08 Interim / Quarterly Rep…
Country SE Sweden
Listing ST IRLAB

About IRLAB Therapeutics

https://irlab.se/

IRLAB Therapeutics is a research and development company that discovers and develops novel treatments for neurodegenerative diseases, with a primary focus on Parkinson's disease and other central nervous system (CNS) disorders. The company's research originates from Nobel Prize-winning science and is driven by its proprietary Integrative Screening Process (ISP) platform. This systems pharmacology-based discovery engine utilizes an extensive database to generate a pipeline of drug candidates. The company's portfolio includes clinical-stage assets such as Mesdopetam (IRL790), in development for treating levodopa-induced dyskinesia (LIDs), and Pirepemat (IRL752), which is being developed to reduce falls and improve balance in patients with Parkinson's disease.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for the period January–March 2024 for IRLAB Therapeutics. It contains comprehensive financial tables (income statement, cash flow, etc.), a CEO statement, operational highlights, and a detailed review of the company's R&D pipeline. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q1 2024
2024-05-08 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report January – March 2024' and contains comprehensive financial data, including a financial summary table (Net sales, Operating profit, Earnings per share, etc.), CEO comments, and strategic priorities for the period. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q1 2024
2024-05-08 English
IRLAB Enters a Development Collaboration for IRL757 as a Novel Treatment for Apathy
Regulatory Filings Classification · 100% confidence The document is a press release dated May 7, 2024, announcing a development collaboration between IRLAB Therapeutics AB and MSRD regarding the drug candidate IRL757. It details financial terms, development milestones, and includes standard sections like 'About IRLAB' and contact information. Crucially, it ends with an 'Attachments' section linking to a PDF of the announcement itself, and a statement indicating the information is being made public pursuant to the EU Market Abuse Regulation. This structure strongly suggests a formal, immediate public disclosure of material, non-financial news, which typically falls under general Regulatory Filings (RNS) or, if it were a financial result, an Earnings Release (ER). Since it is a strategic business development announcement (collaboration/licensing) and not a periodic financial report (10-K, IR, MRQ), RNS is the most appropriate general regulatory disclosure category, as it is a broad announcement of material information.
2024-05-07 English
IRLAB ingår samarbetsavtal för den vidare utvecklingen av IRL757 till en ny behandling för apati
Regulatory Filings Classification · 95% confidence The document is a press release dated May 7, 2024, announcing a collaboration agreement between IRLAB Therapeutics AB and McQuade Center for Strategic Research and Development (MSRD) regarding the drug candidate IRL757. It details financial terms (up-front payment, milestones) and development plans (Phase I study initiation). The text explicitly states: "denna information är sådan information som IRLAB Therapeutics är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning." This indicates a mandatory regulatory disclosure, but it is not a standard SEC form (like 10-K or DEF 14A). Since it is a formal announcement of a significant business event (collaboration/financing terms) that doesn't fit perfectly into the specific categories like ER, IR, or CAP, and it is a general regulatory announcement, the most appropriate classification is Regulatory Filings (RNS), which serves as the general regulatory announcement fallback category for non-US specific filings that are mandatory disclosures under market abuse regulations.
2024-05-07 Swedish
Annual Report (ESEF) 2023
Annual Report (ESEF) Classification · 100% confidence FY 2023
2024-04-29 Swedish
Annual Report (ESEF) 2023
Annual Report (ESEF) Classification · 100% confidence FY 2023
2024-04-29 Swedish

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.